Janssen: European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton's tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL The Janssen Pharmaceutical Companies of Johnson

Related Keywords

United States ,Netherlands ,Amsterdam ,Noord Holland ,American ,Craig Tendler ,Jenni Mildon ,Edmond Chan ,Arnon Kater ,Hematology Am Soc Hematol Educ Program ,Janssen Biotech Inc ,European Hematology Association ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,Diagnostics Medical Affairs ,Global Head Of Late Development ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Amsterdam University Medical Centres ,University Of Amsterdam ,European Commission ,World Health Organisation ,Exchange Commission ,Companies Of Johnson ,Johnson ,Area Lead Haematology ,Deputy Head ,American Society ,Global Head ,Slate Development ,Hematology Oncology ,Janssen Biotech ,World Health Organization ,Model Lists ,Essential Medicines ,Product Characteristics ,Chronic Lymphocytic Leukaemia ,Pharmaceutical Companies ,Metabolism Retina ,Infectious Diseases Vaccines ,Janssen Cilag Limited ,Concerning Forward Looking Statements ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Duration Ibrutinib Venetoclax ,Chronic Lymphocytic Leukemia ,Phasei Dose Escalation Study ,Btk Inhibitor ,Refractoryb Cell Non Hodgkin Lymphoma ,Novel Fluorescent Probe Pharmacodynamic ,Plus Venetoclax ,Small Lymphocytic Lymphoma ,Practice Guidelines ,Treatment Options ,Janssen ,European ,Commission ,Pproves ,Imbruvica ,Ibrutinib ,Ixed ,Uration ,Combination ,Regimen ,Adult ,Patients ,Reviously ,Untreated ,Hronic ,Lymphocytic ,Leukaemia ,